June 2025 in “British Journal of Dermatology” Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.
19 citations
,
September 2008 in “Journal of Cellular Physiology” Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.
January 2026 in “Dermatologic Therapy” Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.
118 citations
,
May 2015 in “European journal of pharmaceutics and biopharmaceutics” The hydrogel with a 1:3 ratio of hydroxyethyl cellulose to hyaluronic acid is effective for delivering drugs through the skin to treat acne.
11 citations
,
January 2024 in “Gynecological Endocrinology” Myo-inositol and D-chiro-inositol, especially in a 40:1 ratio, effectively treat PCOS by improving insulin sensitivity and ovulation.
4 citations
,
January 2020
April 2018 in “Journal of Investigative Dermatology” Finasteride helps female-pattern hair loss.
1 citations
,
January 2022 Myo-inositol and D-chiro-inositol improve hormonal and physical symptoms in teenage girls with PCOS.
November 2021 in “SPAST Abstracts” The EFH-SLM cream is more effective and gentler for treating excessive hair growth in women.
January 2026 in “Nutrición Hospitalaria” Many drugs can cause lipid metabolism issues, and labels need better warnings.
June 2024 in “Neuromuscular Disorders” Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
1 citations
,
November 2023 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib helps with early hair regrowth in people with alopecia areata.
January 2024 in “Wiadomości Lekarskie” Liraglutide with metformin reduces body fat and improves blood sugar control better than metformin and inositol in women with prediabetes.
27 citations
,
June 2017 in “Expert opinion on investigational drugs” New anti-acne medications are being tested to offer alternatives to current treatments.
January 2025 in “Cellular and Molecular Biology” The PIP5K1A gene helps cashmere growth in goats by promoting cell proliferation, and melatonin boosts its expression.
May 2022 in “International Journal of Trichology” July 2025 in “Journal of Investigative Dermatology” Baricitinib stops hair loss and promotes regrowth in alopecia areata.
March 2005 in “Inpharma Weekly” China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.
June 2025 in “British Journal of Dermatology” Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
3 citations
,
April 2021 in “Chemical & Pharmaceutical Bulletin” Extracts from the Calanthe discolor plant promote hair follicle growth and increase growth factor levels.
16 citations
,
August 2023 in “JAAD Case Reports” JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.
109 citations
,
March 2011 in “Journal of controlled release” New micelle solutions greatly improve skin delivery of certain antifungal drugs.
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
5 citations
,
June 2019 in “JAAD Case Reports” Imiquimod used intravaginally for cervical issues can cause temporary hair loss, especially if severe side effects occur.
March 2019 in “Reactions Weekly” 6 citations
,
May 2024 in “JAAD Case Reports” Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
October 2023 in “Naunyn-Schmiedeberg's Archives of Pharmacology” Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
12 citations
,
November 2023 in “Skin Appendage Disorders” JAK inhibitors might help treat Lichen Planopilaris, but more research is needed.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.